Clinical trial
A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)
NCT02714608 is registered in ClinicalTrials.gov with Tasly Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)
- Lead sponsor
- Tasly Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 31, 2016
- Completion date
- December 31, 2018
- Enrollment
- 144 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer (nsclc)